Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | ABL1 | P00519 | 5/20 | 0.36 |
| ▸ | BCR | P11274 | 5/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 2/20 | 0.34 |
| ▸ | DRD2 | P14416 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | AVPR2 | P30518 | 2/20 | 0.33 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MKNK1 | Q9BUB5 | 3/20 | 0.32 |
| ▸ | MKNK2 | Q9HBH9 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4937452 | 0.92 | NPC1 (0.39) | NPC1ABL1BCRMTORPOLB | |
| SCHEMBL4936182 | 0.90 | NPC1 (0.38) | NPC1ABL1BCRMTORPOLB | |
| SCHEMBL4936841 | 0.87 | MKNK1 (0.44) | NPC1ABL1BCRMTORPOLB | |
| SCHEMBL14027879 | 0.85 | ABL1 (0.38) | NPC1ABL1BCRMTORPOLB | |
| SCHEMBL4937180 | 0.82 | NPC1 (0.40) | NPC1ABL1BCRMTORPOLB | |
| SCHEMBL4938205 | 0.81 | NPC1 (0.40) | NPC1ABL1BCRMTORPOLB | |
| SCHEMBL4939332 | 0.80 | AVPR1A (0.40) | NPC1ABL1BCRPOLBDRD2 | |
| SCHEMBL4936885 | 0.79 | NPC1 (0.41) | NPC1ABL1BCRDRD2DRD3 | |
| SCHEMBL14027862 | 0.78 | PRKD1 (0.45) | ABL1BCRAVPR2AVPR1ARIPK1 | |
| SCHEMBL14027866 | 0.78 | AVPR2 (0.44) | NPC1ABL1BCRPOLBAVPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | ASTRAZENECA AB (SE) | 2008-10-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255085-A1 | Novel Imidazo [4,5-b] Pyridine Derivatives as Inhibitors of Glycogen Synthase Kinase 3 for Use in the Treatment of Dementia and Neurodegenerative Disorders | GSK3B, GSK3A, PYGB | NPC1 2895/4885ABL1 793/4885BCR 3820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.